

DOCKET NO: 283148US0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
KOJI SUEMATSU, ET AL. : EXAMINER: STRZELECKA, T. E.
SERIAL NO: 10/563,818 :
FILED: JANUARY 6, 2006 : GROUP ART UNIT: 1637
FOR: METHOD OF JUDGING RISK FOR :
DRUG-INDUCED
GRANULOCYTOPENIA

DECLARATION UNDER 37 C.F.R. § 1.132

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313


SIR:

Now comes Koichi Hasegawa who deposes and
states:

1. That I am a graduate of Osaka University and received a
Ph.D degree in the year 2007.
2. That I have been employed by Osuka Pharmaceutical for 11 years as a
researcher in the field of Molecular Biology.
3. That I understand the English language or, at least, that the contents of the
Declaration were made clear to me prior to executing the same.
4. That the analysis shown in the attached chart was carried out by me or under my
direct supervision and control.
5. The following chart below shows the locations of polymorphisms C31532del,
A2973G, A15870G, A-1164C, AT-2510del and C-4587A disclosed on page 14 of the

Application No. 10/563,818
Declaration Under 37 C.F.R. § 1.132

specification relative to AL162497 (version 20, 143,409 bp; SEQ ID NO: 18) and XM_007095 (6,997 bp). These accession numbers are described at [0038-0039] which bridges pages 14-15 of the specification.



6. XM_007095 is a sequence of IRS-2 mRNA comprising two exons (coding regions). AL162497 is a longer sequence encompassing these two exons as well as an intron (intervening sequence) and flanking sequences. Page 14, lines 3-4 of the specification disclose that the IRS2 gene (two exons + one intron) corresponds to 93,673 to 126,402 bp of AL162497.

Application No. 10/563,818
Declaration Under 37 C.F.R. § 1.132

7. The undersigned petitioner declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

8. Further deponent saith not.

Keiichi Hasegawa
Signature:

November 6, 2007
Date